SPONSOR
Ciceri Fabio
Total Trials
2
Recruiting
2
Phases
N/A
Conditions studied: Acute Myeloid Leukemia, in RelapseMultiple SclerosisAutologous Hematopoietic Stem Cell TransplantATLG
Ciceri Fabio is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Acute Myeloid Leukemia, in Relapse, Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant, ATLG.
Studies span multiple clinical phases, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Ciceri Fabio
How many clinical trials has Ciceri Fabio sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Ciceri Fabio, of which 2 are actively recruiting participants. These trials cover conditions including Acute Myeloid Leukemia, in Relapse, Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Ciceri Fabio research focus on?
Ciceri Fabio clinical trials span Acute Myeloid Leukemia, in Relapse, Multiple Sclerosis, Autologous Hematopoietic Stem Cell Transplant, ATLG. Sponsor focus areas evolve as trials complete and new programs launch.
How do I participate in a Ciceri Fabio clinical trial?
To participate in a Ciceri Fabio trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ciceri Fabio trials with current recruitment status updated daily.
Clinical Trials by Ciceri Fabio
NCT05124288
Recruiting
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
Acute Myeloid Leukemia, in Relapse
NCT07635693
Recruiting
ATLG Levels in Autologous HSCT for Multiple Sclerosis
Multiple Sclerosis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology